Skip to main content

Congenital Adrenal Hyperplasia

  • Chapter
  • First Online:
Clinical Rounds in Endocrinology

Abstract

A 15-day-old child was brought by her parents for repeated vomiting, excessive crying and jitteriness, and poor feeding. She was a product of non-consanguineous marriage and was delivered by induced labor at 33 weeks of gestation due to maternal complications (pregnancy-induced hypertension). Her birth weight was 1.9 kg and she was assigned female gender. She was investigated and found to have hyponatremia and hyperkalemia (Na+ 119 mEq/L, K+ 8.1 mEq/L) and was diagnosed to have hypoaldosteronism. She was initiated with fludrocortisone 50 μg/day. With this treatment, her symptoms subsided but she failed to thrive and progressively became darker; however, serum electrolyte abnormalities were resolved. She was taken to an endocrinologist at 5 months of age, and she was suspected to have congenital adrenal hyperplasia (CAH) and was investigated accordingly. Her unstimulated serum 17α-hydroxyprogesterone [17(OH)P] was 120 ng/ml and was diagnosed to have CAH due to 21α-hydroxylase deficiency, and dexamethasone was added to fludrocortisone. This therapy resulted in weight gain and decrease in pigmentation, and patient became more active. At 2 years of age, she was referred to our institute. Her height was 81 cm (10th percentile, target height 158 cm), weight 12 kg (25th percentile), and she had a Tanner staging of A-, P1, B1. She did not have Cushing’s stigmata. Examination of the external genitalia showed posterior labial fusion, hyperpigmented labioscrotal folds, isolated clitoromegaly, and the gonads were not palpable. Two distinct openings were seen at perineum. The karyotype was 46,XX. Serum 17(OH)P was 26.8 ng/ml. Dexamethasone was replaced with hydrocortisone (7.5 mg/day) and fludrocortisone (100 μg/day) was continued. The annual follow-up of the patient with clinical and biochemical parameters is depicted in the table given below.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Further Readings

  1. DeGroot L, Jameson J. Endocrinology. Philadelphia: Saunders/Elsevier; 2010.

    Google Scholar 

  2. Han TS, Walker BR, Arlt W, Ross RJ. Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat Rev Endocrinol. 2014;10:115–24.

    Article  CAS  PubMed  Google Scholar 

  3. Kaye CI, Committee on Genetics, Accurso F, et al. Newborn screening fact sheets. Pediatrics. 2006;118:e934.

    Article  PubMed  Google Scholar 

  4. Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Baillieres Best Pract Res Clin Endocrinol Metab. 2009;23:181–92.

    Article  CAS  Google Scholar 

  5. Melmed S, Williams R. Williams textbook of endocrinology. Philadelphia: Elsevier/Saunders; 2011.

    Google Scholar 

  6. Mercè Fernández-Balsells M, Muthusamy K, Smushkin G, et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010;73:436–44.

    Google Scholar 

  7. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365:2125–36.

    Article  PubMed  Google Scholar 

  8. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler Jr GB. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2000;85:1114–20.

    Article  CAS  PubMed  Google Scholar 

  9. Nimkarn S, Lin-Su K, New M. Steroid 21-hydroxylase deficiency congenital adrenal hyperplasia. Pediatr Clin North Am. 2011;58:1281–300.

    Article  PubMed  Google Scholar 

  10. Speiser P, Azziz R, Baskin L, Ghizzoni L, Hensle T, Merke D, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95:4133–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer India

About this chapter

Cite this chapter

Bhansali, A., Aggarwal, A., Parthan, G., Gogate, Y. (2016). Congenital Adrenal Hyperplasia. In: Clinical Rounds in Endocrinology. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2815-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-2815-8_10

  • Published:

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-2813-4

  • Online ISBN: 978-81-322-2815-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics